Recombinant Factor VIIa Fails to Improve Functional Outcomes in Hyperacute Intracerebral Haemorrhage Despite Reduced Bleeding: Results from the FASTEST Trial
Recombinant factor VIIa (rFVIIa) administered within 2 hours of symptom onset significantly reduced the expansion of both intracerebral haemorrhage (ICH) and intraventricular haemorrhage (IVH).
Despite the reduction in hematoma growth, there was no significant improvement in 180-day functional outcomes as measured by the modified Rankin Scale (mRS).
The trial was stopped early for futility following a planned interim analysis.
Treatment with rFVIIa was associated with a higher risk of life-threatening thromboembolic complications compared to placebo (5% vs 1%).
Background: The Challenge of Intracerebral Haemorrhage
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
